InspireMD, Inc. (NSPR)
NASDAQ: NSPR · Real-Time Price · USD
2.500
-0.020 (-0.79%)
At close: Aug 13, 2025, 4:00 PM
2.500
0.00 (0.00%)
Pre-market: Aug 14, 2025, 8:58 AM EDT
InspireMD Revenue
InspireMD had revenue of $1.78M in the quarter ending June 30, 2025, with 2.24% growth. This brings the company's revenue in the last twelve months to $7.07M, up 7.60% year-over-year. In the year 2024, InspireMD had annual revenue of $7.01M with 12.96% growth.
Revenue (ttm)
$7.07M
Revenue Growth
+7.60%
P/S Ratio
17.57
Revenue / Employee
$82,163
Employees
86
Market Cap
104.30M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 7.01M | 804.00K | 12.96% |
Dec 31, 2023 | 6.21M | 1.03M | 20.00% |
Dec 31, 2022 | 5.17M | 676.00K | 15.04% |
Dec 31, 2021 | 4.50M | 2.01M | 80.89% |
Dec 31, 2020 | 2.49M | -1.24M | -33.22% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
NSPR News
- 8 days ago - InspireMD, Inc. (NSPR) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 9 days ago - InspireMD Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 14 days ago - InspireMD Announces the Appointment of Raymond W. Cohen to its Board of Directors - GlobeNewsWire
- 14 days ago - InspireMD Announces Combined Financings of $58 Million - GlobeNewsWire
- 23 days ago - InspireMD to Announce Second Quarter 2025 Financial Results - GlobeNewsWire
- 5 weeks ago - InspireMD Announces U.S. Commercial Launch of CGuard® Prime Carotid Stent System for the Prevention of Stroke - GlobeNewsWire
- 7 weeks ago - InspireMD Announces FDA Approval for CGuard® Prime Carotid Stent System for the Prevention of Stroke - GlobeNewsWire
- 2 months ago - InspireMD Announces CE Mark Approval for CGuard® Prime Embolic Prevention System (EPS) Under European MDR for the Prevention of Stroke - GlobeNewsWire